Structural modeling of p.V31F variant in the aspartoacylase gene

Research output: Contribution to journalArticle

4 Citations (Scopus)


Aspartoacylase (ASPA) is an abundant enzyme in the brain, which catalyzes the conversion of N-acetylaspartate into acetate and aspartate, deficiency in its activity leads to degeneration of the white matter of the brain and is a recognized cause of Canavan disease (CD), which affect children. Although genotype-phenotype correlation have been reported for Canavan disease patients, this relationships is still not straightforward. In this communication, we use molecular modeling to address the structural consequences resulting from the missense variant p.V31F in the ASPA enzyme, which we previously reported in a homozygous form in an Egyptian patient with infantile CD. This modeling suggests that this variant brings significant changes to the catalytic core by introducing structural flexibility through neighbouring key residues. In particular, it provides a molecular explanation for the pathogenic effect of this variant and provides a meaningful genotype-phonotype relationships. The mutational impact appears to have an influence on the function of the protein and initiates molecular event for the mechanism of the disease.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalMetabolic Brain Disease
Publication statusAccepted/In press - 21 Jan 2016
Externally publishedYes



  • Aspartoacylase
  • Canavan disease
  • Genotype-phenotype correlation
  • Molecular dynamics simulation
  • Mutational modeling
  • Structure-function relationship

ASJC Scopus subject areas

  • Clinical Neurology
  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this